The health outcomes associated with delayed treatment due to a false negative mpMRI result in Population 1 are summarised in Table 5. Table Population 1: Summary of findings for the linked evidence comparison of mpMRI, relative to TRUSGB or TPUSGB, in patients at low-concern with suspected prostate cancer with assumed pre- probability (prevalence) of 35% Outcomes Patients/ Quality of No. per 100 No. per 100 Importance Comments evidencea patients with patients Studies intervention with [95% CI]b comparatorc [95% CI] True 2,062 Will undergo biopsy 26 [20, 30] 28 [25, 31] Critical ⨁⨁⨀⨀ positives patients as under current management. (10 studies). False 2,062 15 [9, 24] 0 [0, 0] Critical Will undergo biopsy ⨁⨁⨀⨀ positives patients as under current management. (10 studies). True 2,062 50 [41, 56] 65 [65, 65] Critical Will avoid the ⨁⨁⨀⨀ negatives patients potential adverse events resultant (10 studies). from biopsy. False 2,062 9 [5, 15] 7 [4, 11] Critical Will avoid the ⨁⨁⨀⨀ negatives patients potential adverse events resultant (10 studies). from biopsy but possible detriment due to delayed treatment. Major 45,492 TRUSGB: 0 Critical - ⨁⨁⨀⨀ Infection patients Range 0-2 (8 studies). TPUSGB: 0 Minor 132,239 0 TRUSGB: Critical - ⨁⨁⨀⨀ infection patients Range 0-7 (9 studies). TPUSGB: Range 0-1 292,956 0 TRUSGB: Critical - ⨁⨁⨀⨀ hospitalisation patients Range 0-6 (9 studies). TPUSGB: Range 1-2 334,688 TRUSGB: Bleeding 0 Important - ⨁⨀⨀⨀ patients Range 1-88 (13 studies). TPUSGB: Range 1-6 Urinary 132,020 0 TRUSGB: Important - ⨁⨀⨀⨀ obstruction patients Range 1-21 (12 studies). TPUSGB: Range 0-38 Overall 41,146 NA NA Critical Delay did not ⨁⨀⨀⨀ survival patients impact overall survival (results (5 studies). from 5 studies).
The health outcomes associated with delayed treatment due to a false negative mpMRI result in Population 1 are summarised in Table 5. Table Population 1: Summary of findings for the linked evidence comparison of mpMRI, relative to TRUSGB or TPUSGB, in patients at low-concern with suspected prostate cancer with assumed probability (prevalence) of 35% Outcomes Patients/ Studies Quality of evidencea No. per 100 patients with intervention [95% CI]b No. per 100 patients with comparatorc [95% CI] Importance Comments True positives 2,062 patients (10 studies). ⨁⨁⨀⨀ 26 [20, 30] 28 [25, 31] Critical Will undergo biopsy as under current management. False positives 2,062 patients (10 studies). ⨁⨁⨀⨀ 15 [9, 24] 0 [0, 0] Critical Will undergo biopsy as under current management. True negatives 2,062 patients (10 studies). ⨁⨁⨀⨀ 50 [41, 56] 65 [65, 65] Critical Will avoid the potential adverse events resultant from biopsy. False negatives 2,062 patients (10 studies). ⨁⨁⨀⨀ 9 [5, 15] 7 [4, 11] Critical Will avoid the potential adverse events resultant from biopsy but possible detriment due to delayed treatment. Major Infection 45,492 patients (8 studies). ⨁⨁⨀⨀ 0 TRUSGB: Range 0-2 TPUSGB: 0 Critical - Minor infection 132,239 patients (9 studies). ⨁⨁⨀⨀ 0 TRUSGB: Range 0-7 TPUSGB: Range 0-1 Critical - 292,956 patients (9 studies). ⨁⨁⨀⨀ 0 TRUSGB: Range 0-6 TPUSGB: Range 1-2 Critical - Bleeding 334,688 patients (13 studies). ⨁⨀⨀⨀ 0 TRUSGB: Range 1-88 TPUSGB: Range 1-6 Important - Urinary obstruction 132,020 patients (12 studies). ⨁⨀⨀⨀ 0 TRUSGB: Range 1-21 TPUSGB: Range 0-38 Important - Overall survival 41,146 patients (5 studies). ⨁⨀⨀⨀ NA NA Critical Delay did not impact overall survival (results from 5 studies). hospitalisation pre-
1397_Final_MSAC_Assessment_Report.docx